Find Local Parkinsons Disease Clinical Trials

Combined Deep Brain Stimulation for Parkinson's Disease

Status: Upcoming, Phase I, II
Updated: 3/14/2014

National Institutes of Health Clinical Center

2277

from 91732

Bethesda, MD

iPad Based Support System to Improve Outcomes From DBS Therapy

Status: Upcoming
Updated: 5/26/2015

University of Utah

572

from 91732

Salt Lake City, UT

Spinal Cord Stimulation (SCS) for Freezing of Gait (FOG) in Parkinson's Disease

Status: Upcoming
Updated: 12/31/1969

Columbia University Medical Center

2432

from 91732

New York, NY

Microbiota Intervention to Change the Response of Parkinson's Disease

Status: Upcoming, Phase I, II
Updated: 12/31/1969

University of California at San Francisco

356

from 91732

San Francisco, CA

Study of the Fecal Microbiome in Patients With Parkinson's Disease

Status: Upcoming, Phase I
Updated: 12/31/1969

University of Texas Health Science Center at Houston

1352

from 91732

Houston, TX

Wearable Assessments in the Clinic and Home in PD

Status: Upcoming, Phase
Updated: 12/31/1969

University Hospitals of Cleveland Medical Center

2032

from 91732

Cleveland, OH

Wearable Assessments in the Clinic and Home in PD

Status: Upcoming, Phase
Updated: 12/31/1969

Wake Forest University

2125

from 91732

Winston-Salem, NC

Closed Loop DBS Implanted RC+S Study

Status: Upcoming
Updated: 12/31/1969

Duke Univ Med Ctr

2203

from 91732

Durham, NC

Neurology, Psychiatry / Psychology Clinical Trial

Aerobic Exercise in Parkinson's Disease

Status: Upcoming, Phase II, III
Updated: 12/31/1969

Iowa City VA Health Care System, Iowa City, IA

1529

from 91732

Iowa City, IA

Cognitive Rehab for Parkinson's

Status: Upcoming
Updated: 12/31/1969

Edward Hines Jr. VA Hospital, Hines, IL

1719

from 91732

Hines, IL

Neurology, Other Clinical Trial

Emotion Study/Substudy: Flexible Brain Study

Status: Upcoming
Updated: 12/31/1969

University of Florida

2104

from 91732

Gainesville, FL

Protective Step Training

Status: Upcoming
Updated: 12/31/1969

Arizona State University

343

from 91732

Phoenix, AZ

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

2435

from 91732

New York, NY

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

570

from 91732

Salt Lake City, UT

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

2434

from 91732

Brooklyn, NY

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

967

from 91732

Kirkland, WA

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

552

from 91732

Orem, UT

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

from 91732

Pasadena, CA

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

2484

from 91732

Patchogue, NY

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

2414

from 91732

Summit, NJ

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

1932

from 91732

Ann Arbor, MI

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

1589

from 91732

Baton Rouge, LA

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

813

from 91732

Boulder, CO

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

from 91732

Fountain Valley, CA

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2315

from 91732

Hollywood, FL

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2302

from 91732

North Palm Beach, FL

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2214

from 91732

Raleigh, NC

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

1208

from 91732

Round Rock, TX

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

UC Irvine Health Gottschalk Medical Plaza

from 91732

Irvine, CA

Columbia University Medical Center - Neurological Institute, Movement Disorders

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

2351

from 91732

New York, NY

Muhammed Ali Parkinson and Movement Disorder Center/Barrow Neurological Institute

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

343

from 91732

Phoenix, AZ

Development of Software to Provide the SpeechVive Device Via the Internet

Status: Enrolling
Updated: 1/26/2018

SpeechVive, Inc

1757

from 91732

Lafayette, IN

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Status: Enrolling, Phase II
Updated: 12/31/1969

6001

from 91732

Innsbruck,

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Status: Enrolling, Phase II
Updated: 12/31/1969

2375

from 91732

Philadelphia, PA

A Study of LY3154207 in Participants With Parkinson's Disease Dementia

Status: Enrolling, Phase II
Updated: 12/31/1969

ClinCloud, LLC

2183

from 91732

Maitland, FL

A Study of LY3154207 in Participants With Parkinson's Disease Dementia

Status: Enrolling, Phase II
Updated: 12/31/1969

Christiana Care Health Service

2349

from 91732

Newark, DE

A Study of LY3154207 in Participants With Parkinson's Disease Dementia

Status: Enrolling, Phase II
Updated: 12/31/1969

Toronto Memory Program

2161

from 91732

Toronto,

Neurology, Psychiatry / Psychology Clinical Trial

A Study of LY3154207 in Participants With Parkinson's Disease Dementia

Status: Enrolling, Phase II
Updated: 12/31/1969

Hartford Healthcare Chase Movement Disorders Center

2507

from 91732

Vernon, CT

Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Mild Cognitive Impairment (tDCS)

Status: Enrolling
Updated: 4/18/2018

Sanford Brain & Spine Center

1415

from 91732

Fargo, ND

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Status: Enrolling, Phase I, II
Updated: 11/29/2017

Kirkland, Washington

967

from 91732

Kirkland, WA

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Status: Enrolling, Phase III
Updated: 12/31/1969

Booth Garner Parkinson's Care Center

967

from 91732

Kirkland, WA

Fresco Institutute for Parkinson's and Movement Disorders

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Status: Enrolling, Phase III
Updated: 12/31/1969

2351

from 91732

New York, NY

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Status: Enrolling, Phase III
Updated: 12/31/1969

SC3 Research

from 91732

Pasadena, CA

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Status: Enrolling, Phase III
Updated: 12/31/1969

Hartford HealthCare

2506

from 91732

Vernon, CT

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

Status: Enrolling, Phase II
Updated: 12/31/1969

6001

from 91732

Innsbruck,

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

Status: Enrolling, Phase II
Updated: 12/31/1969

from 91732

Long Beach, CA

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

Status: Enrolling, Phase II
Updated: 12/31/1969

1763

from 91732

Nashville, TN

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

Status: Enrolling, Phase II
Updated: 12/31/1969

2375

from 91732

Philadelphia, PA

Neurology, Psychiatry / Psychology Clinical Trial

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

Status: Enrolling, Phase I
Updated: 12/31/1969

SPARC Site 01

2173

from 91732

DeLand, FL

Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation

Status: Enrolling
Updated: 4/3/2018

Johns Hopkins Hospital / Johns Hopkins University

2301

from 91732

Baltimore, MD

Cascade Surgery Associates, PLLC DBA Northwest Neurology Electrodiagnostic Center

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Status: Enrolling, Phase
Updated: 12/31/1969

940

from 91732

Auburn, WA

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Status: Enrolling, Phase
Updated: 12/31/1969

Windrush Behavioral Health/Levindale

2301

from 91732

Baltimore, MD

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Status: Enrolling, Phase
Updated: 12/31/1969

The Chappel Group Research

2187

from 91732

Kissimmee, FL

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Status: Enrolling, Phase
Updated: 12/31/1969

Silicon Valley Parkinson Center Inc.

311

from 91732

Los Gatos, CA

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Status: Enrolling, Phase
Updated: 12/31/1969

University of Massachusetts Worcester

2540

from 91732

Worcester, MA

Effects of Exenatide on Motor Function and the Brain

Status: Enrolling, Phase I
Updated: 12/31/1969

Laboratory for Rehabilitation Neuroscience

2105

from 91732

Gainesville, FL

University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory

Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm

Status: Enrolling, Phase I, II
Updated: 12/31/1969

1931

from 91732

Ann Arbor, MI

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Status: Enrolling, Phase I
Updated: 12/31/1969

Pharmaron Cpc, Inc

2300

from 91732

Baltimore, MD

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Status: Enrolling, Phase I
Updated: 12/31/1969

Bioclinica Research

2184

from 91732

Orlando, FL

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Status: Enrolling, Phase I
Updated: 12/31/1969

Acorda Site #164

1951

from 91732

Farmington Hills, MI

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

2301

from 91732

Baltimore, MD

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

2578

from 91732

Boston, MA

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

2032

from 91732

Cleveland, OH

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

1722

from 91732

Milwaukee, WI

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

2423

from 91732

Newark, NJ

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

1333

from 91732

St. Joseph, MO

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Status: Enrolling
Updated: 1/23/2012

2560

from 91732

Warwick, RI

Parkinson's Foundation Quality Improvement Initiative

Status: Enrolling, Phase
Updated: 12/31/1969

University of Alberta

1361

from 91732

Edmonton,

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

1793

from 91732

Indianapolis, IN

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

2321

from 91732

Miami, FL

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

2349

from 91732

Ottawa,

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

427

from 91732

Tucson, AZ

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

Status: Enrolling, Phase III
Updated: 2/9/2016

from 91732

Ventura, CA

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2434

from 91732

Brooklyn, NY

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2062

from 91732

London,

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

552

from 91732

Orem, UT

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

from 91732

Pasadena, CA

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2414

from 91732

Summit, NJ

Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.

Status: Enrolling, Phase III
Updated: 2/9/2016

2136

from 91732

Tampa, FL

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

Parkinsons Disease and Movement Disorders Center

2312

from 91732

Boca Raton, FL

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

Michigan State University - Dept. of Neurology

1897

from 91732

East Lansing, MI

Bendheim Parkinson's and Movement Disorder Center (Mount Sinai Medical Center)

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

2351

from 91732

New York, NY

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

Jefferson University Hospital Philadelphia

2375

from 91732

Philadelphia, PA

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status: Enrolling, Phase III
Updated: 12/31/1969

Henry Ford Hospital

1952

from 91732

West Bloomfield, MI

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Effect of Exercise in Parkinsonism

Status: Enrolling, Phase I, II
Updated: 12/31/1969

2373

from 91732

Philadelphia, PA

Keck School of Medicine of USC/ University of Southern California

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Status: Enrolling, Phase II
Updated: 12/31/1969

from 91732

Los Angeles, CA

University of Florida Parkinson's Disease and Movement Disorder's Center

A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

Status: Enrolling, Phase II
Updated: 12/31/1969

2135

from 91732

Tampa, FL

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Status: Enrolling, Phase II
Updated: 12/31/1969

2312

from 91732

Boca Raton, FL

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Status: Enrolling, Phase II
Updated: 12/31/1969

2486

from 91732

New Haven, CT

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

Status: Enrolling, Phase II
Updated: 12/31/1969

827

from 91732

Portland, OR

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Status: Enrolling, Phase I
Updated: 6/15/2016

CNS Network

from 91732

Long Beach, CA